What is permexa™ sodium caprate and what is its primary purpose in pharmaceutical development?

Permexa™ sodium caprate is a high-performance intestinal permeation enhancer developed by Ashland Inc. for oral peptide and biologic drug products, including GLP-1 agonists. Its primary purpose is to improve formulation consistency, process robustness, and scalability in drug manufacturing—addressing key challenges in the rapidly growing oral biologics market.

Why is Ashland's launch of permexa™ sodium caprate significant for the oral biologics industry?

The launch is significant because permexa™ sodium caprate directly addresses critical technical hurdles—namely poor intestinal permeability—that have long limited the development of effective oral biologics. By enhancing intestinal permeation, it supports more reliable and scalable manufacturing of oral formulations like GLP-1 agonists, and Ashland reports having already generated significant interest from pharmaceutical developers, signaling strong industry relevance and potential for broader product expansion in this space.

Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate

Aug 24, 2026

Ashland Inc. launched Permexa sodium caprate, an intestinal permeation enhancer for oral peptide and biologic drugs such as GLP-1 agonists. This excipient aims to improve formulation consistency and scalability in the rapidly growing oral biologics market.

GlobeNewswire

2026-04-01

Ashland Inc Stock: Specialty Chemicals Leader Faces Evolving Industrial Demands in 2026

2026-04-04

Allspring Global Investments Reduces Stake in Ashland Inc. to $25.69 Million

2026-04-06

Ashland Raises Prices Across Product Lines Amid Cost Pressures

2026-04-11

Ashland Inc. (NYSE:ASH) Given Consensus Rating of "Hold" by Analysts

2026-04-13

Massachusetts Financial Services Co. Lowers Stock Position in Ashland Inc.